Home > Insider Trading > Filing (0002001011-25-000028)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
886163	Ligand Pharmaceuticals Inc	LGND	Pharmaceutical Preparations (2834)	770160744

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1905248	Octavio Espinoza	555 Heritage Drive Suite 200 Jupiter FL 33458	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-05-09	1,000	$103.89	27,432	No	4	P	Direct
Common Stock	Acquisiton	2025-05-09	500	$104.40	27,932	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct

Footnotes

The reporting person's purchase of Ligand Pharmaceuticals Incorporated ("Ligand") common stock reported herein might be deemed matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,500 shares, with the reporting person's sale of 2,104 shares of Ligand common stock at the highest price of $116.71 per share on December 23, 2024. Accordingly, the reporting person has paid to Ligand, $18,975, representing the full amount of any profit realized if this were to be deemed to be a short-swing transaction.
The total includes 69 shares acquired on December 31, 2024, through the Issuer's Employee Stock Purchase Plan (ESPP).